120 related articles for article (PubMed ID: 38113900)
1. Synergistic Chemoimmunotherapy Augmentation via Sequential Nanocomposite Hydrogel-Mediated Reprogramming of Cancer-Associated Fibroblasts in Osteosarcoma.
Wang H; Chen Y; Wei R; Zhang J; Zhu J; Wang W; Wang Z; Wupur Z; Li Y; Meng H
Adv Mater; 2024 Apr; 36(15):e2309591. PubMed ID: 38113900
[TBL] [Abstract][Full Text] [Related]
2. CPPs-modified chitosan as permeability-enhancing chemotherapeutic combined with gene therapy nanosystem by thermosensitive hydrogel for the treatment of osteosarcoma.
Cao J; Zhu C; Cao Z; Ke X
Int J Biol Macromol; 2024 May; 267(Pt 2):130915. PubMed ID: 38561118
[TBL] [Abstract][Full Text] [Related]
3. Ferritin-Based Nanocomposite Hydrogel Promotes Tumor Penetration and Enhances Cancer Chemoimmunotherapy.
Liu R; Liang Q; Luo JQ; Li YX; Zhang X; Fan K; Du JZ
Adv Sci (Weinh); 2024 Jan; 11(3):e2305217. PubMed ID: 38029345
[TBL] [Abstract][Full Text] [Related]
4. In situ Co-Delivery of Doxorubicin and Cisplatin by Injectable Thermosensitive Hydrogels for Enhanced Osteosarcoma Treatment.
Si M; Xia Y; Cong M; Wang D; Hou Y; Ma H
Int J Nanomedicine; 2022; 17():1309-1322. PubMed ID: 35345787
[TBL] [Abstract][Full Text] [Related]
5. NOX4 Inhibition Potentiates Immunotherapy by Overcoming Cancer-Associated Fibroblast-Mediated CD8 T-cell Exclusion from Tumors.
Ford K; Hanley CJ; Mellone M; Szyndralewiez C; Heitz F; Wiesel P; Wood O; Machado M; Lopez MA; Ganesan AP; Wang C; Chakravarthy A; Fenton TR; King EV; Vijayanand P; Ottensmeier CH; Al-Shamkhani A; Savelyeva N; Thomas GJ
Cancer Res; 2020 May; 80(9):1846-1860. PubMed ID: 32122909
[TBL] [Abstract][Full Text] [Related]
6. Cell membrane-anchored and tumor-targeted IL-12 T-cell therapy destroys cancer-associated fibroblasts and disrupts extracellular matrix in heterogenous osteosarcoma xenograft models.
Hu J; Lazar AJ; Ingram D; Wang WL; Zhang W; Jia Z; Ragoonanan D; Wang J; Xia X; Mahadeo K; Gorlick R; Li S
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38199607
[TBL] [Abstract][Full Text] [Related]
7. Sequentially pH-Responsive Drug-Delivery Nanosystem for Tumor Immunogenic Cell Death and Cooperating with Immune Checkpoint Blockade for Efficient Cancer Chemoimmunotherapy.
Jiang M; Chen W; Yu W; Xu Z; Liu X; Jia Q; Guan X; Zhang W
ACS Appl Mater Interfaces; 2021 Sep; 13(37):43963-43974. PubMed ID: 34506118
[TBL] [Abstract][Full Text] [Related]
8. PLK1shRNA and doxorubicin co-loaded thermosensitive PLGA-PEG-PLGA hydrogels for osteosarcoma treatment.
Ma H; He C; Cheng Y; Li D; Gong Y; Liu J; Tian H; Chen X
Biomaterials; 2014 Oct; 35(30):8723-34. PubMed ID: 25017095
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin and CD‑CUR inclusion complex co‑loaded in thermosensitive hydrogel PLGA‑PEG‑PLGA localized administration for osteosarcoma.
Yang Z; Liu J; Lu Y
Int J Oncol; 2020 Aug; 57(2):433-444. PubMed ID: 32468050
[TBL] [Abstract][Full Text] [Related]
10. Regulating cancer associated fibroblasts with losartan-loaded injectable peptide hydrogel to potentiate chemotherapy in inhibiting growth and lung metastasis of triple negative breast cancer.
Hu C; Liu X; Ran W; Meng J; Zhai Y; Zhang P; Yin Q; Yu H; Zhang Z; Li Y
Biomaterials; 2017 Nov; 144():60-72. PubMed ID: 28823844
[TBL] [Abstract][Full Text] [Related]
11. Transformable prodrug nanoplatform
Yang W; Yi J; Zhu R; Guo Y; Zhang K; Cao Y; Li X; Zhang J; Zhang Z; Li Y; Chen X
Theranostics; 2023; 13(6):1906-1920. PubMed ID: 37064869
[No Abstract] [Full Text] [Related]
12. Injectable pH-responsive hydrogel for combinatorial chemoimmunotherapy tailored to the tumor microenvironment.
Gu J; Zhao G; Yu J; Xu P; Yan J; Jin Z; Chen S; Wang Y; Zhang LW; Wang Y
J Nanobiotechnology; 2022 Aug; 20(1):372. PubMed ID: 35953828
[TBL] [Abstract][Full Text] [Related]
13. The effect of PLGA-based hydrogel scaffold for improving the drug maximum-tolerated dose for in situ osteosarcoma treatment.
Yang Z; Yu S; Li D; Gong Y; Zang J; Liu J; Chen X
Colloids Surf B Biointerfaces; 2018 Dec; 172():387-394. PubMed ID: 30193198
[TBL] [Abstract][Full Text] [Related]
14. Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts.
Gazzano E; Buondonno I; Marengo A; Rolando B; Chegaev K; Kopecka J; Saponara S; Sorge M; Hattinger CM; Gasco A; Fruttero R; Brancaccio M; Serra M; Stella B; Fattal E; Arpicco S; Riganti C
Cancer Lett; 2019 Aug; 456():29-39. PubMed ID: 31047947
[TBL] [Abstract][Full Text] [Related]
15. Co-Delivery Nanomicelles for Potentiating TNBC Immunotherapy by Synergetically Reshaping CAFs-Mediated Tumor Stroma and Reprogramming Immunosuppressive Microenvironment.
Zhang Y; Han X; Wang K; Liu D; Ding X; Hu Z; Wang J
Int J Nanomedicine; 2023; 18():4329-4346. PubMed ID: 37545872
[TBL] [Abstract][Full Text] [Related]
16. Application of tumor-targeting peptide-decorated polypeptide nanoparticles with doxorubicin to treat osteosarcoma.
Qiu R; Sun D; Bai Y; Li J; Wang L
Drug Deliv; 2020 Nov; 27(1):1704-1717. PubMed ID: 33305647
[TBL] [Abstract][Full Text] [Related]
17. Injectable thermosensitive black phosphorus nanosheet- and doxorubicin-loaded hydrogel for synergistic bone tumor photothermal-chemotherapy and osteogenesis enhancement.
Li S; Qing Y; Lou Y; Li R; Wang H; Wang X; Ying B; Tang X; Qin Y
Int J Biol Macromol; 2023 Jun; 239():124209. PubMed ID: 36972826
[TBL] [Abstract][Full Text] [Related]
18. Co-delivery of doxorubicin and paclitaxel by reduction/pH dual responsive nanocarriers for osteosarcoma therapy.
Li Y; Hou H; Zhang P; Zhang Z
Drug Deliv; 2020 Dec; 27(1):1044-1053. PubMed ID: 32633576
[TBL] [Abstract][Full Text] [Related]
19. EphA2 Targeted Doxorubicin-Nanoliposomes for Osteosarcoma Treatment.
Haghiralsadat F; Amoabediny G; Naderinezhad S; Nazmi K; De Boer JP; Zandieh-Doulabi B; Forouzanfar T; Helder MN
Pharm Res; 2017 Dec; 34(12):2891-2900. PubMed ID: 29110283
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of Nox4 induces a pro-survival Nrf2 response in cancer-associated fibroblasts that promotes tumorigenesis and metastasis, in part via Birc5 induction.
Mir S; Golden BDO; Griess BJ; Vengoji R; Tom E; Kosmacek EA; Oberley-Deegan RE; Talmon GA; Band V; Teoh-Fitzgerald ML
Breast Cancer Res; 2022 Jul; 24(1):48. PubMed ID: 35836253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
